12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dalcetrapib: Additional Phase III data

Detailed data from the double-blind, international Phase III dal-OUTCOMES trial in 15,871 patients with stable CHD following a recent acute coronary syndrome (ACS) showed that once-daily 600 mg oral dalcetrapib plus standard of care (SOC) missed the primary endpoint of reducing a composite of time to first occurrence of CHD death, non-fatal acute MI, hospitalization for unstable angina, resuscitated cardiac arrest or stroke vs. placebo plus SOC (8.3% vs. 8%, p=0.52). The analysis, which was conducted at a median follow-up of 31 months, included 1,135 primary endpoint events (71% of the projected total number). In May, Roche discontinued development of dalcetrapib due a...

Read the full 494 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >